IL74809A - Live purified marek's disease vaccine - Google Patents

Live purified marek's disease vaccine

Info

Publication number
IL74809A
IL74809A IL74809A IL7480985A IL74809A IL 74809 A IL74809 A IL 74809A IL 74809 A IL74809 A IL 74809A IL 7480985 A IL7480985 A IL 7480985A IL 74809 A IL74809 A IL 74809A
Authority
IL
Israel
Prior art keywords
marek
disease
virus
mdv
monovalent
Prior art date
Application number
IL74809A
Other languages
English (en)
Other versions
IL74809A0 (en
Original Assignee
Centraal Diergeneeskundig Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centraal Diergeneeskundig Inst filed Critical Centraal Diergeneeskundig Inst
Publication of IL74809A0 publication Critical patent/IL74809A0/xx
Publication of IL74809A publication Critical patent/IL74809A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/816—Viral vaccine for avian species, e.g. poultry or other birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IL74809A 1984-04-09 1985-04-03 Live purified marek's disease vaccine IL74809A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL8401120A NL8401120A (nl) 1984-04-09 1984-04-09 Viruspreparaat, waarmee gevaccineerd kan worden tegen de ziekte van marek.

Publications (2)

Publication Number Publication Date
IL74809A0 IL74809A0 (en) 1985-07-31
IL74809A true IL74809A (en) 1990-09-17

Family

ID=19843774

Family Applications (1)

Application Number Title Priority Date Filing Date
IL74809A IL74809A (en) 1984-04-09 1985-04-03 Live purified marek's disease vaccine

Country Status (17)

Country Link
US (1) US4673572A (enExample)
EP (1) EP0159743B1 (enExample)
JP (1) JPS6123A (enExample)
AT (1) ATE56364T1 (enExample)
AU (1) AU574164B2 (enExample)
CA (1) CA1251397A (enExample)
DD (1) DD232822A5 (enExample)
DE (1) DE3579617D1 (enExample)
ES (1) ES8605680A1 (enExample)
HU (1) HU194496B (enExample)
IL (1) IL74809A (enExample)
IN (1) IN163229B (enExample)
MX (1) MX7718E (enExample)
NL (1) NL8401120A (enExample)
WO (1) WO1985004588A1 (enExample)
YU (1) YU44687B (enExample)
ZA (1) ZA852564B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456101A (en) * 1980-11-08 1984-06-26 Honda Giken Kogyo Kabushiki Kaisha Vehicular brake operating system
JP2508625B2 (ja) * 1985-08-30 1996-06-19 ソニー株式会社 半導体レ−ザ−
FR2598596B1 (fr) * 1986-05-15 1990-10-19 Sanofi Elf Bio Ind Procede de traitement du lait en vue de l'obtention de fromages
US5849299A (en) * 1991-06-28 1998-12-15 The United States Of America As Represented By The Secretary Of Agriculture Attenuated revertant serotype 1 marek's disease vaccine
WO1993023078A1 (en) * 1992-05-19 1993-11-25 Viktoria Alexeevna Lukina Vaccine for prophylaxis of marek disease of birds and method of its preparation
EP0703294A1 (en) * 1994-07-14 1996-03-27 Akzo Nobel N.V. Marek's disease virus vaccine
IL114501A (en) * 1994-07-14 1999-08-17 Akzo Nobel Nv Marek's disease virus vaccine
EP0748867A1 (en) * 1995-06-12 1996-12-18 Duphar International Research B.V Marek's disease vaccine
US5989805A (en) * 1995-10-27 1999-11-23 Board Of Trustees Operating Michigan State University Immortal avian cell line to grow avian and animal viruses to produce vaccines
WO1997046103A1 (en) * 1996-06-04 1997-12-11 University Of Georgia Research Foundation, Inc. Modified live avian polyomavirus vaccine in psittacine birds
EP1038952A3 (en) * 1998-12-09 2001-06-27 Pfizer Products Inc. Processes for preparation of Marek's Disease Virus using continuous avian cell lines
RU2144377C1 (ru) * 1999-06-28 2000-01-20 Всероссийский научно-исследовательский институт защиты животных Бивалентная вакцина против болезни марека и способ ее изготовления
KR102951567B1 (ko) 2012-03-22 2026-04-10 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 개질된 마렉병 바이러스, 및 이로부터 제조된 백신

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1292803A (en) * 1968-11-18 1972-10-11 Nat Res Dev Improvements relating to the production of antigens
US3642574A (en) * 1970-04-29 1972-02-15 Us Agriculture Method for producing vaccine for immunization of poultry against marek{3 s disease
US3783098A (en) * 1971-08-10 1974-01-01 Cornell Res Foundation Inc Highly potent,viable and stable cellfree virus preparations from cells infected with cell-associated viruses and method for obtaining the same
US4160024A (en) * 1978-05-01 1979-07-03 Cornell Research Foundation, Inc. Marek's disease vaccine

Also Published As

Publication number Publication date
US4673572A (en) 1987-06-16
AU4156185A (en) 1985-11-01
MX7718E (es) 1990-10-10
AU574164B2 (en) 1988-06-30
NL8401120A (nl) 1985-11-01
EP0159743A1 (en) 1985-10-30
YU44687B (en) 1990-12-31
YU59985A (en) 1988-06-30
IL74809A0 (en) 1985-07-31
ES8605680A1 (es) 1986-04-16
HU194496B (en) 1988-02-29
ZA852564B (en) 1985-11-27
JPS6123A (ja) 1986-01-06
ES541930A0 (es) 1986-04-16
WO1985004588A1 (en) 1985-10-24
DD232822A5 (de) 1986-02-12
HUT38542A (en) 1986-06-30
IN163229B (enExample) 1988-08-27
JPH0317808B2 (enExample) 1991-03-11
ATE56364T1 (de) 1990-09-15
CA1251397A (en) 1989-03-21
DE3579617D1 (de) 1990-10-18
EP0159743B1 (en) 1990-09-12

Similar Documents

Publication Publication Date Title
IN163229B (enExample)
Takahashi et al. Transformation of hamster embryo and human embryo cells by temperature sensitive mutants of herpes simplex virus type 2
Powell Immunity to Marek's disease induced by glutaraldehyde-treated cells of Marek's disease lymphoblastoid cell lines
Allen et al. Role of coexpression of IL-2 and herpes simplex virus proteins in recombinant vaccinia virus vectors on levels of induced immunity
US5686287A (en) Marek's disease virus vaccine
EP0775743A2 (en) Sustainable chick cell line infected with Marek's disease virus
GR3007856T3 (enExample)
US4895718A (en) Serotype 2 Marek's disease vaccine
CA2222482A1 (en) Non-virulent mycoplasma synoviae and vaccine thereof
EP0156478A3 (en) Propagation of group ii avian adeno (aa) virus in avian cell culture and vaccine produced
US5149530A (en) Live newcastle disease virus vaccines
HU914111D0 (en) Cell-less marek-type virus vaccine
US5565202A (en) Low enhancement serotype 2 vaccine for marek's disease
Carmichael et al. Small-plaque variant of canine herpesvirus with reduced pathogenicity for newborn pups
EP0591384B1 (en) Attenuated revertant serotype 1 marek's disease vaccine
Eisenstein et al. Salmonella vaccines: Protection by endotoxin protein and lipopolysaccharide in two different mouse strains.
JPS5756430A (en) Live virus vaccine for canine parainfluenza
EP0703294A1 (en) Marek's disease virus vaccine
Jeffries et al. Atypical menaquinone pattern in a strain of Staphylococcus aureus
EP0668356A3 (en) Recombinant infectious bovine rhinotracheitis virus mutant, methods for the production of same, and vaccines containing the same
TOUB et al. development ofacell line system susceptible to infection with vaccine strains of mdv
Allison Tumour Viruses: Are Observations on Tumour Viruses in Animals Applicable to Man?
CA1289881C (en) Vaccine against herpes simplex
KR960016906A (ko) 약독화 수두 생바이러스 백신 및 그의 제조방법
岡崎和子 et al. The immunodominant glycoprotein complex of equid herpesvirus 1 (EHV-1) and the counterpart of EHV-4.

Legal Events

Date Code Title Description
RH Patent void